LIFECORE BIOMEDICAL INC (LFCR) Stock Price & Overview

NASDAQ:LFCR • US5147661046

Current stock price

4.15 USD
-0.21 (-4.82%)
At close:
4.15 USD
0 (0%)
After Hours:

The current stock price of LFCR is 4.15 USD. Today LFCR is down by -4.82%. In the past month the price decreased by -42.84%. In the past year, price decreased by -36.64%.

LFCR Key Statistics

52-Week Range4.09 - 8.9799
Current LFCR stock price positioned within its 52-week range.
1-Month Range4.09 - 7.48
Current LFCR stock price positioned within its 1-month range.
Market Cap
155.501M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-1.07
Dividend Yield
N/A

LFCR Stock Performance

Today
-4.82%
1 Week
-39.06%
1 Month
-42.84%
3 Months
-48.38%
Longer-term
6 Months -47.27%
1 Year -36.64%
2 Years -21.85%
3 Years +9.93%
5 Years N/A
10 Years N/A

LFCR Stock Chart

LIFECORE BIOMEDICAL INC / LFCR Daily stock chart

LFCR Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to LFCR. When comparing the yearly performance of all stocks, LFCR is a bad performer in the overall market: 92.87% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

LFCR Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to LFCR. Both the profitability and financial health of LFCR have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

LFCR Earnings

On January 2, 2026 LFCR reported an EPS of -0.29 and a revenue of 31.11M. The company missed EPS expectations (-7.29% surprise) and beat revenue expectations (5.77% surprise).

Next Earnings DateApr 8, 2026
Last Earnings DateJan 2, 2026
PeriodQ1 / 2026
EPS Reported-$0.29
Revenue Reported31.11M
EPS Surprise -7.29%
Revenue Surprise 5.77%

LFCR Forecast & Estimates

11 analysts have analysed LFCR and the average price target is 8.93 USD. This implies a price increase of 115.06% is expected in the next year compared to the current price of 4.15.

For the next year, analysts expect an EPS growth of 36.35% and a revenue growth 1.62% for LFCR


Analysts
Analysts78.18
Price Target8.93 (115.18%)
EPS Next Y36.35%
Revenue Next Year1.62%

LFCR Groups

Sector & Classification

LFCR Financial Highlights

Over the last trailing twelve months LFCR reported a non-GAAP Earnings per Share(EPS) of -1.07. The EPS decreased by -2114.69% compared to the year before.


Income Statements
Revenue(TTM)135.27M
Net Income(TTM)-39.04M
Industry RankSector Rank
PM (TTM) N/A
ROA -16.6%
ROE -106.13%
Debt/Equity 3.67
Chartmill High Growth Momentum
EPS Q2Q%40.82%
Sales Q2Q%25.93%
EPS 1Y (TTM)-2114.69%
Revenue 1Y (TTM)5.31%

LFCR Ownership

Ownership
Inst Owners76.18%
Shares37.47M
Float36.70M
Ins Owners1.78%
Short Float %7.44%
Short Ratio19.81

LFCR Latest News, Press Relases and Analysis

About LFCR

Company Profile

LFCR logo image Lifecore Biomedical, Inc. engages in the development and manufacturing of pharmaceuticals products and services. The company is headquartered in Chaska, Minnesota and currently employs 406 full-time employees. The firm designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The firm offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. The company is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The firm uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.

Company Info

IPO: 1996-02-15

LIFECORE BIOMEDICAL INC

3515 Lyman Boulevard

Chaska MINNESOTA US

Employees: 524

LFCR Company Website

LFCR Investor Relations

Phone: 19523684300

LIFECORE BIOMEDICAL INC / LFCR FAQ

What does LFCR do?

Lifecore Biomedical, Inc. engages in the development and manufacturing of pharmaceuticals products and services. The company is headquartered in Chaska, Minnesota and currently employs 406 full-time employees. The firm designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The firm offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. The company is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The firm uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.


Can you provide the latest stock price for LIFECORE BIOMEDICAL INC?

The current stock price of LFCR is 4.15 USD. The price decreased by -4.82% in the last trading session.


What is the dividend status of LIFECORE BIOMEDICAL INC?

LFCR does not pay a dividend.


What is the ChartMill rating of LIFECORE BIOMEDICAL INC stock?

LFCR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Which stock exchange lists LFCR stock?

LFCR stock is listed on the Nasdaq exchange.


What is the expected growth for LFCR stock?

The Revenue of LIFECORE BIOMEDICAL INC (LFCR) is expected to grow by 1.62% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.


What is LIFECORE BIOMEDICAL INC worth?

LIFECORE BIOMEDICAL INC (LFCR) has a market capitalization of 155.50M USD. This makes LFCR a Micro Cap stock.